Suntech's first launch of Suntech Pharmaceuticals completed hundreds of millions of yuan in Series C financing to promote the development of a new generation of brain disease treatment drugs

Recently, Tianjin Suntech Yaoyuan Technology Co.
, Ltd.
(hereinafter referred to as "Suntech Yaoyuan", English Accendatech) announced the completion of the C round of financing of several hundred million yuan
.

This round of financing was led by Guozhong Capital, followed by Guangdong Hengjian Group, Anhui Chuanggu Capital and other institutions.
The financing funds were mainly used for the promotion of ACT001, ACT004 and other pipeline clinical projects, the introduction of talents, and preparation for drug listing
.

 "Since the results of the clinical trial of the company's ACT001 drug in the treatment of DIPG (diffuse intrinsic pontine glioma in children) were presented in the form of a report at the SNO meeting in June 2021, we have received reports from around the world including Hong Kong, California and Utah.
Hospitals in more than 10 developed countries and regions including Israel, Canada, Ireland and Iceland, etc.
sympathetically donated drugs or consulted on clinical trials for a single patient
.

So far, some hospitals have passed the approval of the local drug administration and successfully obtained our The ACT001 clinical trial drug was donated free of charge
.

Although the above drug results cannot be used for drug marketing application, we are still very happy to contribute our best efforts to the unfortunate children suffering from DIPG around the world
.

" Dr.
Chen Yue, CEO of Suntech Medicine, said: "Fortunately, in 2021, ACT001 will be granted the status of rare diseases in children by the US FDA, which is the first Chinese original innovative drug to obtain this certification
.

In March this year, it obtained the approval for the pivotal clinical trial for the treatment of DIPG Phase II in the US, and our China The phase II clinical trial of DIPG has also begun to recruit DIPG patients in Tianjin Cancer Hospital, and Chinese children can start taking the new water-soluble capsules without excipients
.

Finally, the results of our clinical phase 1b/2a clinical trial combined with radiotherapy in the treatment of cancer brain metastases have been confirmed by ASCO included (Abstract#366152), it is expected to be announced at the end of the month, so stay tuned
.

Ms.
Hao Manlin, co-founder and COO of Suntech Pharmacy, said: "At present, China's innovative drug market is returning to clinical value, and the capital market is also pulling back
.

Affected by the complex international situation and frequent domestic epidemics, the pace of investment and financing in biomedicine has slowed down in the past six months
.

In the environment of capital winter and crises, the company was able to successfully complete the financing, and we are very grateful to the investment institutions for their recognition of us
.

I believe that there must be spring after the cold winter, and the word crisis implies an opportunity.
Suntech's opportunity for medicine comes from its unshakable persistence in the past ten years.
In response to the most urgent clinical needs in the world, the research and development of global innovation and competition are very strong.
Small, new medicine with Chinese characteristics
.

” About Suntech Yaoyuan Suntech Yaoyuan was established in 2008.
Its R&D and management headquarters are located in Nankai District, Tianjin.
It has established subsidiaries in the United States, Australia and many provinces and cities in China.
It is a global innovative company with complete preclinical A company engaged in research, clinical trials and production chain
.
It
has received support from China's 12th and 13th Five-Year New Drug Creation Major Special Funds
.

Suntech Yaoyuan pays special attention to the active ingredients in traditional Chinese medicine, and selects single ingredients with high activity and large content.
Adopt modern medicinal chemistry strategy to optimize the structure, so as to obtain the world's first drug candidate with new structure and new mechanism
.

Enter into clinical trials in developed countries and around the world, and realize the perfect combination of Chinese characteristics and global layout/world first
.

Suntech Pharmaceuticals has gradually built a Two unique technology platforms, namely "opening/regulating blood-brain barrier platform" and "cancer stem cell-targeted drug development platform", allow for the continuous delivery of new drug candidates
.

The company was selected into the "China Chemical R&D Strength Ranking" in 2020 List TOP100"
.

   ●About ACT001 ● Among the drug varieties that have been marketed and conducted clinical trials worldwide, ACT001 is the only immunomodulator that can enter the brain
.

Immunomodulators such as lenalidomide are often used extensively in the treatment of cancer, inflammation, and fibrosis
.

ACT001 is in clinical trials for the following indications: including recurrent glioblastoma, childhood diffuse endogenous pontine glioma, combined with radiotherapy for cancer brain metastases, neuromyelitis optica and pulmonary fibrosis
.

ACT001 exerts its multi-target network-like effect through STAT3, NF-KB and Nrf2 pathways.
The increase of intracranial M1 macrophages was observed in cancer animal models and patients with recurrent GBM, and was observed in most cancer patients.
The trend of decreasing Treg ratio in peripheral blood
.

ACT001 has successively obtained the US orphan drug qualification, the EU orphan drug qualification and the US rare childhood disease qualification
.

The synthetic raw material of ACT001 is parthenolide, and parthenolide exists in a large amount in China's endemic plant Xinyi tree.
Xinyi tree is widely planted in China.
A large number of Xinyi trees are sold to cities as greening every year.
The roots become waste, but become a valuable source for us to extract parthenolide
.

While promoting global clinical trials, we have also made modest contributions to poverty alleviation, rural revitalization and greening by purchasing discarded roots of saffron and promoting the planting of saffron trees
.

●About China China Capital ● China China Capital is a professional venture investment trust management platform.
Currently, it is hosting two national SME development funds entity funds, and the cumulative management scale has exceeded 10 billion yuan
.

Focus on investment opportunities in strategic emerging industries.
The investment projects involve information technology, high-end equipment manufacturing, Internet, new energy, new materials, biomedicine and other industries, and form new energy vehicles, semiconductor electronic components, intelligent driving and other fields.
A relatively complete industrial chain layout has been established
.

He has repeatedly won nearly 20 awards in various industry selections, and has been on the Zero2IPO China Top 100 Best Venture Capital Institutions for three consecutive years, and has been on the China Investment China Best Venture Capital Institutions list for two consecutive years.
Two years on the Securities Times China Venture Capital Golden Eagle Awards annual list of the best venture capital institutions
.

The companies invested by China China Venture Capital also frequently appear on the lists of major industry authorities, and have won more than 40 awards of various types
.

●About Guangdong Hengjian Investment ●Guangdong Hengjian Investment Holding Co.
, Ltd.
was established on August 20, 2007.
It is a wholly state-owned company established with the approval of the Guangdong Provincial People's Government and performed by the State-owned Assets Supervision and Administration Commission of Guangdong Province.
It is a provincial-level state-owned company.
State-owned capital operating companies and major strategic investment platforms of the provincial party committee and provincial government shoulder the mission of promoting the optimization and structural adjustment of the state-owned economy by injecting new kinetic energy in state-owned capital operations, and helping the Guangdong-Hong Kong-Macao Greater Bay Area take off
.

In recent years, the company has built a symbiotic, shared and win-win investment ecosystem with capital as a link.
In the process of promoting industrial transformation and upgrading and empowering the development of advantageous enterprises, the company has achieved rapid development, with excellent asset quality, high credit rating, continuous investment capability and Its advantages such as strong resource integration ability are more prominent, and its operating performance and asset scale are among the forefront of the national provincial-level state-owned capital operating companies
.

●About Chuanggu Capital ●Chuanggu Capital was established in 2018.
It is a market-oriented professional equity investment fund management platform under the Anhui Provincial Investment Group, and it is also the first provincial-level equity fund management institution with mixed ownership in Anhui
.

Chuanggu Capital focuses on key industries such as big health, TMT, intelligent equipment, and new materials, and builds a full-life-cycle fund cluster system from angels, VCs, PE, to mergers and acquisitions
.

Up to now, 21 funds have been managed, the scale of funds under management has exceeded 8.
7 billion yuan, and a total of 200 investment companies have been completed
.

In the field of general health, a number of investments have been made such as Bloomage Bio, Yifan Pharmaceutical, Honghe Renai Medical, Zhongke Tuoran, Tiangang Immunization, Lianchuang Bio, Baoyi Pharmaceutical, Qihao Medical, Yinluo Medical, and Happiness Factory.
business
.

Yaodu Consulting Zhao Kun’s team introduced business due diligence and project value assessment: serving many innovative drug companies in China and nearly 30 well-known VC/PE at home and abroad, involving a total investment and financing amount of more than 20 billion yuan; providing services for well-known multinational companies Product strategy and BD opportunity services; specific project transaction evaluation and product line planning services for more than 40 well-known domestic pharmaceutical companies; industry training services for many generic pharmaceutical companies and secondary market customers Yaodu Consulting: Zhao Kun (male) Mobile: 18810793869 (same WeChat account) earned 900 million in four years! One of the top three domestic model animal giants, JiCuiYaoKang, will be launched soon When LAG-3 meets PD-1: Dual immune checkpoint therapy "Small Trial", significantly prolonging the PFS of melanoma patients Following the "Y drug", the second CTLA-4 The approval of the inhibitor is imminent, and the race to upgrade the track has opened a road since ancient times.
Is "injection" the only route of administration for macromolecular drugs? Click "read the original text" to keep abreast of industry trends